Sleep Apnea Surgery, CPAP Avoided By Palatal Implant – Restore Medical
This article was originally published in The Gray Sheet
Executive Summary
Restore Medical will pursue Medicare and private insurer coverage for its Pillar palatal implant system by profiling the device's relative cost-effectiveness over surgical procedures to treat sleep apnea
You may also be interested in...
Medtronic buys sleep apnea implant maker
Medtronic gains Restore Medical's Pillar palatal implant system for treatment of obstructive sleep apnea and snoring through its $29 million acquisition of the company, announced April 22. The 510(k)-cleared device complements Medtronic ear, nose and throat products for "other upper airway obstructions, including the sinuses and tonsils/adenoids," according to the company (1"The Gray Sheet" Sept. 20, 2004, p. 18). St. Paul, Minn.-based Restore Medical had 2007 sales of $4.1 million, down 30%. The purchase deal values Restore at $1.60 per share - a 191% premium over its April 22 closing price of $0.55
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.